Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.
August 7, 2014
Verastem Reports Second Quarter 2014 Financial and Corporate Results
July 10, 2014
Verastem Presents Results and Updated Development Plans at Annual Research and Development Day
July 8, 2014
Verastem to Ring the NASDAQ Stock Market Closing Bell and Host Annual Research and Development Day on July 10, 2014
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.